General
Preferred name
PASIREOTIDE
Synonyms
SOM 230 ()
SOM 320 ()
Signifor ()
PASIREOTIDE DIASPARTATE ()
Pasireotide (pamoate) ()
Pasireotide (ditrifluoroacetate) ()
Pasireotide (acetate) ()
Pasireotide (L-aspartate salt) ()
SOM230 (pamoate) ()
SOM230 ()
SOM230 ditrifluoroacetate ()
Pasireotide TFA salt ()
SOM230 (acetate) ()
SOM230 L-aspartate ()
Pasireotide Acetate ()
PASIREOTIDE PAMOATE ()
SOM-230 ()
Pasireotida ()
SOM-230 PAMOATE ()
Signifor lar kit ()
SOM230 PAMOATE ()
Pasireotide embonate ()
Signifor lar ()
Pasireotide (as diaspartate) ()
P&D ID
PD009554
CAS
396091-73-9
396091-79-5
396091-76-2
396091-77-3
Tags
available
drug
Drug indication
Acromegaly
Cushing disease
Hyperglycemia
pituitary-dependent Cushing's disease
Drug Status
approved
Max Phase
4.0
First approval
2012
2014
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ROE Pasireotide is eliminated mostly by hepatic clearance (biliary excretion)(about 48%) with some minor renal clearance (about 7.63%).; ;
DESCRIPTION Cyclic peptide analog of somatostatin. This compound is represented on ChEMBL with slightly different stereochemistry by CHEMBL3039583. (GtoPdb)
DESCRIPTION Pasireotide (SOM230) ditrifluoroacetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide ditrifluoroacetate exhibits antisecretory, antiproliferative, and proapoptotic activity[1][2].
DESCRIPTION Pasireotide (SOM230) acetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide acetate can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide acetate also exhibits antisecretory, antiproliferative, and proapoptotic activity[1][2][3].
DESCRIPTION Pasireotide (SOM230) acetate is a long-acting cyclohexapeptide growth hormone inhibitory hormone analog with antisecretory, antiproliferative, and proapoptotic activities.Pasireotide (SOM230) acetate inhibits the secretion of GH, IGF-I, and ACTH, and can be used in the study of acromegaly and Cushing's disease. Pasireotide (SOM230) acetate also enhances the agonist activity of growth inhibitory receptors, with pKi of 8.2, 9.0, 9.1, <7.0 and 9.9 for sst1, 2, 3, 4 and 5, respectively. (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
1
Compound Sets
16
ChEMBL Approved Drugs
CHEMBL3349607
CHEMBL5314380
CHEMBL5314382
ChEMBL Drugs
CHEMBL3349607
CHEMBL5314380
CHEMBL5314382
Drug Repurposing Hub
DrugBank
DB06663
DrugBank Approved Drugs
DB06663
DrugMAP
DMHM7JS
DrugMAP Approved Drugs
DMHM7JS
Guide to Pharmacology
2018
Mcule NIBR MoA Box Subset
MCULE-9945701845
MedChem Express Bioactive Compound Library
HY-16381
HY-79136
HY-79135
HY-16381A
HY-108768
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
98H1T17066
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
Selleckchem Bioactive Compound Library
pasireotide
TargetMol Bioactive Compound Library
TP2207
External IDs
45
Properties
(calculated by RDKit )
Molecular Weight
1046.5
Hydrogen Bond Acceptors
11
Hydrogen Bond Donors
9
Rotatable Bonds
17
Ring Count
8
Aromatic Ring Count
6
cLogP
3.37
TPSA
281.2
Fraction CSP3
0.33
Chiral centers
7.0
Largest ring
18.0
QED
0.06
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Somatostatin Receptor
SSTR1, SSTR2, SSTR3, SSTR5
SSTR
Member status
member
MOA
Somatostatin SRIF1B (sst5) inhibitor
somatostatin receptor agonist
Indication
Cushing's syndrome, acromegaly
Biosynthetic Origin
Peptide (Ribosomal)
Therapeutic Indication
Cushing's Syndrome
Therapeutic Class
Hormone Therapy
Pathway
GPCR/G protein
Neuronal Signaling
Source data